Is Anavar Safer Than Other Steroids?

What Makes Anavar Different from Other Anabolic Steroids?

Oxandrolone's molecular structure gives it a higher anabolic-to-androgenic ratio than testosterone, which means it builds lean tissue with comparatively less androgenic stimulation of the scalp, prostate, and sebaceous glands. The ratio is approximately 322 to 24 versus testosterone's baseline of 100 to 100. That gap is real, but it does not make oxandrolone consequence-free.

Unlike injectable testosterone esters or nandrolone decanoate, oxandrolone is taken orally because of a methyl group at the 17α carbon position. That same modification forces all of the drug through hepatic first-pass metabolism, generating the liver-stress signal that is common to all 17α-alkylated oral steroids. Injectable testosterone bypasses this pathway entirely, which is one reason physicians at endocrinology centers use injectable testosterone for hypogonadism rather than oral androgens.

The FDA approved oxandrolone under the trade name Anavar in 1964, later rescheduled it as a Schedule III controlled substance, and currently lists approved indications as weight gain restoration after surgery, chronic infection, or severe trauma, as well as bone-pain relief in osteoporosis. Body-composition enhancement is off-label.

The practical takeaway: oxandrolone's reduced androgenicity makes it more tolerable for women and for men who are sensitive to androgenic side effects, but it does not escape the cardiovascular and endocrine penalties shared by all anabolic-androgenic steroids (AAS).

Liver Toxicity: Anavar vs. Oral vs. Injectable Steroids

Anavar causes less hepatotoxicity than methyltestosterone or oxymetholone (Anadrol), but dose matters considerably. Studies in burn and HIV-wasting patients using 20 mg/day showed modest transaminase elevations that resolved after discontinuation. At the 40 to 80 mg/day doses used in performance settings, ALT and AST rises become clinically significant.

A 2004 controlled study published in the Journal of Clinical Endocrinology and Metabolism found oxandrolone at 20 mg/day for 12 weeks raised ALT by roughly 30% in healthy men, while oxymetholone at a comparable relative dose produced elevations exceeding 200% of baseline. The authors concluded the 17α-alkylation class carries a hepatotoxicity gradient, with oxandrolone at the lower end.

Injectable testosterone enanthate and testosterone cypionate, by contrast, show negligible direct hepatotoxicity at therapeutic doses (100 to 200 mg/week) because they skip hepatic first-pass metabolism. Nandrolone decanoate at 200 to 400 mg/week similarly avoids the 17α-alkylation problem. For the liver specifically, injectables are safer than any oral AAS including oxandrolone.

Peliosis hepatis and cholestatic jaundice have been reported with prolonged 17α-alkylated steroid use, though most published cases involve oxymetholone or methyltestosterone rather than oxandrolone. The FDA drug label for oxandrolone nonetheless carries a warning for hepatic peliosis and hepatocellular carcinoma with long-term use. Review the full prescribing information here.

Cardiovascular Risk: The HDL Problem Across All AAS

Every anabolic steroid degrades the lipid profile. Anavar's oral route makes its cardiovascular footprint larger than that of injectable testosterone at equivalent anabolic effect.

A placebo-controlled trial published in JAMA (Lovejoy et al., 1995, N=72) showed oxandrolone 20 mg/day for 12 weeks reduced HDL cholesterol by approximately 30%, a drop that cardiovascular risk models associate with a meaningful increase in atherosclerotic event probability. Injectable testosterone at therapeutic TRT doses (200 mg/week) reduces HDL by roughly 8 to 11% over the same period, according to data from the Testosterone Trials consortium.

Supraphysiologic injectable testosterone (e.g., 600 mg/week used by some bodybuilders) produces HDL suppression closer to 20 to 25%, still below oxandrolone's 30% impact at a much lower absolute dose. Nandrolone decanoate at 600 mg/week can reduce HDL by 26% while also elevating LDL. Stanozolol, another oral 17α-alkylated steroid, drives HDL down by 33 to 50% in some case series, making it worse than oxandrolone from a lipid standpoint.

Left ventricular hypertrophy (LVH) is documented with long-term AAS use across all drug types. A meta-analysis in European Heart Journal (Baggish et al.) covering 1,461 AAS users found left ventricular wall thickness 16% greater than non-using athletes. The analysis did not isolate oxandrolone specifically but covered the AAS class broadly.

Testosterone Suppression and Post-Cycle Therapy

All AAS suppress endogenous testosterone production by reducing gonadotropin-releasing hormone (GnRH) pulsatility and lowering LH and FSH from the pituitary. Oxandrolone is often described as "less suppressive," and at doses below 20 mg/day this is partially true. At 40 to 80 mg/day for 8 weeks or more, testosterone suppression is essentially complete.

After a standard 8-week oxandrolone cycle at 40 mg/day, serum testosterone commonly falls to castrate range (<50 ng/dL) within 2 to 4 weeks of starting. Without post-cycle therapy (PCT), natural testosterone recovery may take 3 to 6 months. During that window, men experience low-T symptoms: fatigue, loss of libido, muscle loss, and depressed mood.

PCT protocols typically use a selective estrogen receptor modulator (SERM). Clomiphene citrate (Clomid) 50 mg/day for 4 to 6 weeks is the most commonly cited approach; it stimulates pituitary LH secretion and can accelerate testicular testosterone resumption. A 2013 review in Fertility and Sterility found clomiphene restored testosterone to normal range in 73% of hypogonadal men within 3 months. Tamoxifen 20 mg/day is an alternative SERM used when estrogen-related rebound is a concern.

The American Urological Association's 2018 guideline on testosterone deficiency states: "Exogenous androgen administration of any form suppresses endogenous testosterone production; recovery is not guaranteed and may be incomplete in long-term users." Full guideline text is available via PubMed.

How Anavar Compares to SARMs on Safety

Selective androgen receptor modulators (SARMs) such as ostarine (MK-2866), ligandrol (LGD-4033), and RAD-140 are often marketed as steroid alternatives with a cleaner safety profile. The reality is more nuanced.

Are SARMs Legal?

SARMs are not FDA-approved for any clinical indication. The FDA has issued multiple warning letters to SARMs distributors and classifies them as unapproved drugs, not dietary supplements. The FDA's 2017 consumer alert states companies are illegally marketing SARMs in products sold as dietary supplements. In the United States, SARMs are legal to possess in most states but illegal to sell for human consumption. WADA prohibits SARMs in sport both in and out of competition.

Do SARMs Really Build Muscle?

Phase II trial data for ostarine (ENOBOSARM-1 and ENOBOSARM-2, sponsored by GTx Inc., N=159 cancer patients) showed a statistically significant 1.4 kg increase in lean body mass versus placebo at 12 weeks (P<0.001). These trials are indexed at ClinicalTrials.gov and the results published in JAMA Oncology. The anabolic effect exists but is notably smaller than what is produced by testosterone or oxandrolone at performance doses. No large phase III trials in healthy adults have been completed.

Ligandrol (LGD-4033) in a placebo-controlled study of 76 healthy men at 1 mg/day for 3 weeks produced a 1.21 kg gain in lean mass. That trial, published in the Journals of Gerontology, also documented dose-dependent testosterone suppression. Muscle gains from SARMs in the available human data are real but modest compared to anabolic steroids.

Do SARMs Need PCT?

Yes, at moderate to high doses. The LGD-4033 trial cited above showed free testosterone fell by 24 to 55% depending on dose at 3 weeks of use. Higher doses (5 to 10 mg/day, commonly used in bodybuilding contexts) produce suppression similar in magnitude to a low-dose oxandrolone cycle. A clomiphene-based PCT or a brief nolvadex course is advisable after SARMs cycles lasting more than 4 to 6 weeks at doses above 5 mg/day.

Will SARMs Show on a Drug Test?

SARMs are detectable by WADA-accredited labs using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Detection windows vary by compound: ostarine metabolites are detectable in urine for up to 10 days after the last dose, while RAD-140 metabolites may be detectable for 28 days or longer. The WADA 2024 Prohibited List explicitly names SARMs as a class under S1.2. Standard military and workplace drug screens do not currently test for SARMs, but athletic drug tests routinely do.

Androgenic Side Effects: Virilization, Hair Loss, and Acne

Anavar's low androgenicity (ratio score of approximately 24 vs. testosterone's 100) translates into less scalp hair loss in men predisposed to androgenetic alopecia, less acne, and less prostate stimulation at moderate doses. For women, oxandrolone is one of the few AAS used in clinical settings (e.g., Turner syndrome, burn recovery) precisely because virilizing side effects are lower than with testosterone or nandrolone.

Women using oxandrolone at performance doses (10 to 20 mg/day) still report clitoral enlargement, voice deepening, and menstrual disruption, with some effects potentially irreversible after prolonged use. The prescribing information carries specific warnings about female virilization. Testosterone, trenbolone, and stanozolol carry higher virilization risk per milligram.

For men, high-dose oxandrolone (80 mg/day) can still accelerate male-pattern baldness in those with the 5α-reductase sensitivity gene variant because a small fraction of oxandrolone is reduced to a more potent 5α-reduced metabolite. The absolute risk is lower than with testosterone at equivalent anabolic dose, but it is not zero.

Psychiatric and Behavioral Effects

Anabolic steroids as a class are associated with mood disturbance, increased aggression, and dependency. Oxandrolone at therapeutic doses (5 to 20 mg/day) shows a low incidence of behavioral changes in clinical trials. At supraphysiologic doses (40 to 80 mg/day), the psychiatric risk increases.

A 2014 study in Psychopharmacology examining 231 AAS users found anabolic steroid dependency in 30% of long-term users, with oxandrolone cited less frequently as a primary drug of abuse than testosterone or trenbolone. The authors noted oral androgens with low androgenicity may carry lower reinforcing properties than high-dose testosterone. Withdrawal from any AAS, including oxandrolone, can precipitate depression lasting weeks to months.

Anavar at Therapeutic Doses vs. Performance Doses: A Critical Distinction

The FDA-approved dose for oxandrolone is 2.5 to 20 mg/day in divided doses for adults. Clinical trials showing favorable tolerability almost universally use doses at or below 20 mg/day.

Performance and bodybuilding use commonly runs 40 to 80 mg/day, sometimes higher. At those doses, the hepatotoxicity, lipid disruption, and suppression data shift materially. A man using 80 mg/day for 10 weeks is not experiencing the same risk profile as a burn patient receiving 10 mg/day for 4 weeks. The "Anavar is mild" framing in online communities almost always refers to the lower end of the dose range while describing physique goals that require the higher end.

Physicians at endocrinology practices who prescribe testosterone replacement therapy for true hypogonadism work within published Endocrine Society guidelines (2018), which recommend testosterone therapy only when two morning serum testosterone measurements are below 300 ng/dL with concurrent symptoms. Those guidelines are available at endocrine.org. Oxandrolone is not a guideline-endorsed option for hypogonadism.

Regulatory and Legal Status

Oxandrolone is a Schedule III controlled substance under the Controlled Substances Act, making non-prescription possession a federal offense in the United States. Its therapeutic prescribing has legitimate indications listed in the FDA label, but prescribing for body composition enhancement alone falls outside approved use.

Injectable testosterone (cypionate, enanthate) prescribed through a licensed telehealth or in-person provider for documented hypogonadism is legal and regulated. Buying oxandrolone through gray-market online sources carries the additional risk of product adulteration; a 2015 analysis of 44 black-market AAS products found 18% contained no active ingredient and 25% were mislabeled for concentration. That analysis is cited in a Drug Testing and Analysis review indexed on PubMed.